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| 5823 F I G U R E 1 Functional analyses of preeclampsia differentially expressed proteins. Differentially expressed proteins (DEPs) enriched for different cellular components (A), biological processes (B) and molecular functions (C), according to GO annotation. KEGG pathway enrichment analysis of DEPs for significantly enriched pathways (D) pre-existing diabetes, multiple (twin) pregnancy, nulliparity and family history have been associated with PE. 6 Nonetheless, it still remains extraordinarily difficult for clinicians to predict patients who will develop the condition in pregnancy. Current research has focused on mapping the changes in the levels of soluble blood vascular factors in response to disease activity. 7, 8 to interfere with iTRAQ analysis. 12 A total of 100 μg of deleted protein extract from each sample were then trypsinized and the resulting peptides subjected to iTRAQ and MS analysis. The Protein
Prophet algorithm was used to assign the probability that each peptide was related to a particular protein. Normalization of the relative peptide intensities of protein data was carried out iteratively (across samples and spectra) using ANOVA, as previously described.
13
F I G U R E 2 Validation of preeclampsia (PE) differentially expressed urine proteins. A, Normalized levels of selected candidate proteins Transferrin (TF), Alpha-1-antitrysin (AAT), Serum paraoxonase/arylestersase 1 (PON1), Alpha-1-antichymotrypsin (ACT), Complement factor B (CFB), Plasminogen (PLG), Mannan-binding lectin serine protease 1 (MASP1) and plasma serine protease inhibitor (PSPI). Each bar represents the mean ± SEM. Statistical significance for the differences (*P < 0.05; **P < 0.01; ***P < 0.005) were determined by paired Student's t test. B, Principal components analysis. PE samples (•) and control samples (■). C, Validation of key differentially expressed proteins by Western blot or ELISA. Dot plots of the relative levels of TF, CBF and PON1 in individual test (T) group and control (C) group samples. The middle line and the top and bottom lines represent the mean ± 95%CI, based on the relative intensities of the gel bands or ELISA values. Statistical significance for the differences between the T and C groups (*P < 0.05; **P < 0.01; ***P < 0.005) was determined by Student's t test We found that the seven women with severe PE consistently showed differences in the urine proteomic fingerprint compared to their seven matching controls. Among a total of 985 proteins identified, 294 (30%) were differentially expressed proteins (DEPs) in PE patients (>1.5 fold change, P < 0.05). These 294 DEPs were further analysed by Blast2GO to characterize the relevant biological processes, cellular components and molecular functions associated with PE (Figure 1) . We found that the vast majority of DEPs were located in the extracellular space and thus were secreted proteins ( Figure 1A) . Gene Ontology analysis for biological processes revealed that the main functional categories of these proteins were complement activation, platelet degranulation, receptor-mediated endocytosis and negative regulation of endopeptidase activity ( Figure 1B) . According to molecular function analysis, these proteins were mainly involved in serine-type endopeptidase activity, serine-type endopeptidase inhibitor activity and calcium ion binding ( Figure 1C) . KEGG pathway analysis found that the DEPs were involved in coagulation and complement pathways, the renin-angiotensin system and cell adhesion molecule interactions ( Figure 1D ).
These altered biological pathways in PE patients are consistent with general observations from PE blood studies [7] [8] [9] and a previous study of urinary proteins whereby pooled PE and control samples were also compared by iTRAQ analysis. and transferrin (TF) that was highly elevated in PE patients and complement factor B (CFB) that was only moderately elevated in PE patients (Figure 2A ). Urine samples from 14 PE patients and 14 normotensive pregnant patients (including the original seven matching patients and controls) were comparatively analysed by either immunoblotting (TF and CFB) or ELISA (PON1) ( Figure 2C ).
Based on dot plot analysis of individual samples results, the mean levels of TF (266 vs 166, P < 0.0002), CFB (3.5 vs 2.4, P < 0.0007) and PON1 (1083 vs 85, P < 0.0016) were significantly higher in PE patients compared to control samples. These independent assays of the three selected DEPs conducted on the original and additional urine samples confirmed the primary iTRAQ results.
This study demonstrates that iTRAQ is a powerful analytical tool for quantitating changes in levels of proteins in complex body fluids like urine. The DEPs we identified in this study represent a valuable catalogue of proteins abnormally altered at end stage PE.
The challenge now is to determine whether any of these DEPs, or new unknown proteins, appear early in the urine of patients at risk for developing PE. One strategy would be to enroll pregnant patients with known risk factors for PE into a new study whereby urine samples are taken weekly from gestational age of 16 weeks before symptoms first appear 4 and use iTRAQ proteomics to analyse significant protein changes. A larger set of normotensive pregnant patients at the same gestational age could be used as the control group. Prospective analysis would reveal any changes in the normal levels of urine proteins and therefore any significant early markers could be retrospectively identified from those patients that do develop clinical PE. By this approach, it may be possible for the first time to identify the key protein changes in urine with a strong association for development of PE, leading to the design of simple assays to identify at risk pregnancies. This would then allow careful monitoring of these pregnancies with administration of the appropriate therapies to reduce symptoms, leading to better management of a term pregnancy.
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